Abstract 83P
Background
Pancreatic cancer is one of the deadliest cancers worldwide, with a 5-year survival rate of less than 10%. The dismal prognosis is primarily due to late-stage diagnosis, resulting from the absence of specific, early, and sensitive biomarkers. Macrophage inhibitory cytokine 1 (MIC-1), a member of the transforming growth factor-beta superfamily, has been proposed as a potential biomarker for the early diagnosis of pancreatic cancer. However, the existing literature reports inconsistent diagnostic performance for serum MIC-1 levels in pancreatic cancer detection. This study aims to evaluate the diagnostic accuracy of serum MIC-1 as a biomarker for pancreatic cancer.
Methods
A systematic review was performed in PubMed, Embase, Web of Science, and Scopus to identify relevant studies published up to January 2023. These studies assessed assessing usage of MIC-1 in pancreatic cancer patients, with healthy individuals serving as the comparator control group. Statistical analysis was performed using R software (version 4.0.3) with the mada package to pool sensitivity, specificity, false-positive rate estimates, diagnostic odds ratio, and positive and negative likelihood ratios; each expressed within a 95% Confidence Interval (CI).
Results
Analysis of five studies involving 2008 participants (1151 pancreatic cancer patients, 857 healthy controls) revealed a robust diagnostic performance for serum MIC-1 levels, with a high pooled sensitivity of 86.7% (95% CI, 75.4-93.3%, I2=93.9%) and specificity of 85.9% (95% CI, 66.9-94.9%, I2=94%). A false-positive rate of 14.1% (95% CI, 5.1-33.1%) was noted. Positive and negative likelihood ratios were 6.17 (95% CI, 2.37-16.05) and 0.15 (95% CI, 0.08-0.30), respectively, and a high diagnostic odds ratio of 39.92 (95% CI, 10.44-152.66) indicated strong efficacy for MIC-1 as a diagnostic biomarker.
Conclusions
Serum MIC-1 demonstrates substantial potential as an early diagnostic biomarker for pancreatic cancer due to its high sensitivity and specificity. Nevertheless, the significant heterogeneity in the studies calls for more extensive, well-designed prospective validation studies before clinical implementation.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract